Abstract 833. Rituximab (R) + Hypercvad alternating with R-methotrexate/cytarabine after 9 Years: Continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL)

Authors: Jorge Romaguera, Luis Fayad, Alma Rodriguez, Fb Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Jatin Shah, Pamela Weaver, Kim Hartig, Fernando Cabanillas, Larry Kwak, Hagop Kantarjian, Michael Wang

Investigators of this study treated newly diagnosed MCL patients with alternating cycles of R-HyperCVAD (rituximab, cyclophosphamide, doxorubicin, vincristine and dexamethasone) and R-MA (rituximab and methotrexate/cytarabine) for a total of 6-8 cycles. Of 97 evaluable patients, 87% achieved a complete response or uncomfirmed complete response after six cycles. After seven years, overall survival and failure-free survivals were 60% and 43%, respectively. Among patients 65 years or younger, the seven year overall survival and failure-free survivals were 68% and 52%, respectively.

Abstract 1560. The efficacy and safety of lenalidomide oral monotherapy in patients with mantle cell lymphoma previously treated with bortezomib: Pooled data from two phase II studies

Authors: Craig B. Reeder, T.E. Witzig, Julie M. Vose, Pier Luigi Zinzani, Rena Buckstein, Corinne Haioun, Reda Bouabdallah, Jonathan Polikoff, Pingshan Guo, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, Myron S. Czuczman

Study investigators pooled together data from two phase II trials (NHL-002 and NHL-003) testing single-agent lenalidomide for patients with relapsed MCL. Of the 54 patients enrolled in the trials, 26% had received prior bortezomib and are the subject of this study. Among these patients, 57% experienced a response with 21% experiencing a complete response/unconfirmed complete response. According to the investigators, these results clearly demonstrate that lenalidomide oral monotherapy is a very effective therapy (with manageable side effects) in patients with relapsed or refractory MCL who had received prior treatment with bortezomib.

Abstract 2147. Sustained graft-versus-lymphoma effect among patients with mantle cell lymphoma given nonmyeloblative allogeneic hematopoeitic cell transplantation

Authors: Mohamed L. Sorror, Barry Storer, Brenda M. Sandmaier, Michael Maris, Thomas Chauncey, Richard T. Maziarz, Michael Pulsipher, Judith Shizuru, Dietger Niederwieser, Edward Agura, James C. Wade, Amelia A Langston, Rainer F. Storb, David G. Maloney

Previously, investigators reported a 2-year overall survival of 65% among 33 patients with MCL who were given nonmyeloablative allogeneic hematopoeitic cell transplantations (HCT). This study provides an update on the initial 33 patients with a median follow up of 63 months, as well as a report on 20 additional patients. At 5-years, 44% and 14% of the patients were alive without or with chronic grant-versus-host disease (GVHD), respectively.   GVHD is a common condition that occurs when transplanted cells attack the tissues of the transplant recipient. According to the study investigators, these data seem to indicate that nonmyeloblative HCT is a potentially curative therapeutic modality for patients with advanced MCL, including patients whose lymphoma was chemotherapy-refractory.

Abstract 3049. The addition of ritiuxmab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG Trial

Authors: Eva Hoster, Michael Unterhalt, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar Steinhauer, Sonja Martin, Else Heidemann, Ali Aldaoud, Wolfgang Hiddemann, Martin Dreyling

This study provided an update of a previously published trial comparing R-CHOP to CHOP in untreated patients with advanced stage MCL. Of the 123 evaluable patients, overall response rates were 92% versus 75% for R-CHOP versus CHOP, respectively, and complete remission rates were 33% versus 8%, respectively. After a median follow-up of 65 months, median time to treatment failure was prolonged from 14 months for CHOP to 28 months for R-CHOP. Similarly, median response duration was prolonged from 18 months for CHOP to 29 months for R-CHOP. However, so far, no significant improvement of overall survival has been observed.

Abstract 582.  Molecular remission after combined immunochemotherapy is of prognostic relevance in patients with MCL: results of the randomized intergroup trials of the European MCL Network

Authors: Christiane Pott, Eva Hoster, Sebastian Böttcher1, Reiner Siebert, Wolfram Klapper, Marie Helene Delfau, Michael Unterhalt, Wolfgang Hiddemann, Michael Kneba, Martin Dreyling

Study investigators have discovered that quantitative detection of circulating MCL cells improves clinical risk assessment and staging accuracy in patients with MCL. Furthermore, the study shows that Real Time Quantitative PCR (RQ-PCR), a scientific technique used to amplify specific regions of DNA, can be used to evaluate the impact of different treatment modalities on tumor clearance in peripheral blood and bone marrow. According to the study investigators, this is the first randomized trial demonstrating that achievement of Molecular Remission (MR), a complete remission with no evidence of disease in the blood or bone marrow, by combined immunochemotherapy might predict a favorable outcome of treatment in MCL.

Abstract 264. Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent MCL

Authors: John P. Leonard, Ann LaCasce, Mitchell R Smith, Ariela Noy, Jeffrey T Yap, Annick D Van den Abbeele, Jian Q Yu, Selina Chen-Kiang, Scott A Ely, Shankar Vallabhajosula, Lucian R Chirieac, Steven M Larson, Geoffrey I Shapiro, Heiko Schoder

By using specific imaging techniques, (FLT-PET imaging) and tissue analysis, study investigators were able to determine how the drug PD 0223991 may work. These data demonstrate that PD 0332991 inhibits certain enzymes (Cdk4/6), leading to a reduction in cancer cell proliferation. According to study investigators, the information provides proof of at least one mechanism of action of PD 0332991 and can be used to potentially inform treatment approaches in patients with recurrent MCL.